Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
3 minute read

Why Cannabis Is Recession-Resistant & Turning Challenges Into Opportunities, Industry Expert Explains

By Nina Zdinjak
Today, 11:09 PM
It is safe to say that the cannabis industry would not have progressed as much as it has if it were not for the people who believed in it. Cannabis advocates, lobbyists, growers, operators, consumers and researchers have consistently played a crucial role in the space. Nevertheless, without capital, the industry wouldn’t have advanced to where it is today.

AAWH

Read More
2 minute read

Acquisitions & Expansion Boost Marimed’s Q4 Revenue 6% Sequentially, 2022 Sales Increased To $134M

By Maureen Meehan
Today, 11:09 PM
MariMed, Inc. (OTCQX: MRMD) announced its financial results Wednesday afternoon for the fourth quarter and full year ended December 31, 2022. The company reported sales for the year increased to $134 million, compared with $121.5 million the prior year.

MRMD

Read More
1 minute read

Celldex Therapeutics Presented Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023; Said Rapid, Profound And Durable Responses Across Multiple Dosing Groups With Favorable Safety Profile Observed

By Charles Gross
Today, 11:09 PM
Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today updated data from the Company's Phase 1b clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines.

CLDX